Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company whose business model is predicated on animal testing for regulatory compliance and product development. The company’s pipeline of novel neurological therapeutics, including its lead candidate NBI-921352 for focal onset seizures, requires extensive nonclinical laboratory tests and animal studies to advance through the FDA approval process. Published research on its compounds explicitly details the licensing and use of genetically modified mouse models, such as the NaV1.6 N1768D mouse, for pharmacological characterization.

All of Xenon’s drug candidates are in pre-clinical or clinical development, a phase where animal data is mandatory for regulatory submissions. The company’s own annual report notes that long-term pre-clinical testing includes “animal tests of reproductive [adverse events].” As a pharmaceutical company with no marketed products, its entire research and development operation is built on animal experimentation to establish safety and efficacy before human trials.